An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Fevipiprant (Primary)
- Indications Allergic asthma; Asthma; Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 23 Aug 2019 Status changed from recruiting to completed.
- 23 Jul 2018 Planned End Date changed from 25 Jun 2018 to 30 Aug 2018.
- 23 Jul 2018 Planned primary completion date changed from 25 Jun 2018 to 30 Aug 2018.